TheraSource is a growing biotech company located in the Greater New York area. Our mission is to develop novel anti-inflammatory therapeutics for the treatment of human diseases. TheraSource is currently focused on the development of newly-discovered molecules to treat patients with ischemic acute kidney injury (AKI) and acute radiation injury. TheraSource's R&D unit resides at The Feinstein Institute for Medical Research, which is equipped with a state-of-the-art preclinical testing facility. Our research team currently consists of 9 scientists with MD or PhD degrees in multidisciplinary areas, including protein chemistry, cell biology, immunology, pathophysiology, and clinical medicine. The company possesses 14 utility patents covering 5 molecules to treat selected inflammatory human diseases.